L2M Validate – Pi16 Therapeutics

The mission of PI16 Therapeutics is to improve skin health for the ~4 million Canadian’s suffering from long-term skin diseases, including clinically dry skin, chronic wounds, and severe burns. PI16 Therapeutics aims to produce skin solutions for these individuals by genetically engineering naturally occurring stem-cell like fibroblasts that express the gene Peptidase Inhibitor 16 (Pi16) with regenerative properties and packaging these cells in a clinical-grade hydrogel formulation. The resulting PI16+ fibroblast containing hydrogel will be directly applied to painful skin at hospitals and dermatology clinics to bring permanent relief by improving skin vitality, skin healing, and skin immunity.

Faculty Supervisor:

Matthew Buechler

Student:

Partner:

DMZ Ventures Inc

Discipline:

Life Sciences

Sector:

Biotechnology; Biomanufacturing; Pharmaceuticals

University:

University of Toronto

Program: